Posted inPress Releases
Clinical Analytics Gains Momentum as FDA Grants RMAT Designation to Lexeo’s LX2020 Gene Therapy
Lexeo Therapeutics has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for LX2020, an investigational gene therapy being developed for PKP2 arrhythmogenic cardiomyopathy,…









